Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2017 / Cilt: 51 - Sayı: 3

Results of Radiofrequency Ablation Treatment in Primary and Metastatic Liver Cancer

Primer ve metastatik karaciğer kanserlerinde radyofrekans ablasyon tedavi sonuçları

Pages
225–233
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Following RFA, one patient had cholecystitis while intraperitoneal minimal hemorrhage was encountered in two patients.Conclusion: As RFA treatment protects intact liver tissues, directly targets the tumor, and the mortality and morbidity rates are lower when compared to other treatments, it is currently considered safe for the treatment of liver tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this present study was to retrospectively evaluate the local therapeutic efficiency of radiofrequency ablation (RFA) treatment in patients with primary and metastatic liver cancer.Material and Methods: A total of 35 patients who had undergone RFA in our clinic were included in the study and evaluated retrospectively.
📊
Key Findings & Data:Local tumor growth, new lesion formation and general survival factors were evaluated statistically.Results: During the follow-up after RFA treatment, the residual tumor was determined in the treatment area in only one (1.9%) lesion.
💡
Conclusion & Impact:Following RFA, one patient had cholecystitis while intraperitoneal minimal hemorrhage was encountered in two patients.Conclusion: As RFA treatment protects intact liver tissues, directly targets the tumor, and the mortality and morbidity rates are lower when compared to other treatments, it is currently considered safe for the treatment of liver tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this present study was to retrospectively evaluate the local therapeutic efficiency of radiofrequency ablation (RFA) treatment in patients with primary and metastatic liver cancer.Material and Methods: A total of 35 patients who had undergone RFA in our clinic were included in the study and evaluated retrospectively. Patients were grouped according to their ages, lesion's primary or metastatic formation, number of lesions and lesion sizes. Local tumor growth, new lesion formation and general survival factors were evaluated statistically.Results: During the follow-up after RFA treatment, the residual tumor was determined in the treatment area in only one (1.9%) lesion. Total ablation was achieved in 50 lesions (98.0%). Local tumor growth occured in 9 lesions of eight patients (17.6%). During follow-up, development of a new lesion at a different liver region was seen in 22 (62.8%) patients. Following RFA, one patient had cholecystitis while intraperitoneal minimal hemorrhage was encountered in two patients.Conclusion: As RFA treatment protects intact liver tissues, directly targets the tumor, and the mortality and morbidity rates are lower when compared to other treatments, it is currently considered safe for the treatment of liver tumors.

Özet

Amaç: Bu çalışmada amacımız, primer veya metastatik karaciğer kanseri olan hastaların radyofrekans ablasyon (RFA) tedavisinin lokal terapötik etkinliğini retrospektif olarak değerlendirmekti.Gereç ve Yöntem: Kliniğimizde radyofrekans ablasyon tedavisi uygulanmış 35 hasta çalışmaya dahil edildi ve retrospektif olarak değerlendirildi. Hastalar yaşlarına, lezyonun primer ya da metastatik oluşuna, lezyon sayılarına ve lezyon büyüklüklerine göre gruplandırıldı. Lokal tümör büyümesi, yeni lezyon oluşumu ve genel sağkalıma etki edebilecek unsurlar istatistiksel olarak değerlendirildi.Bulgular: Radyofrekans ablasyon tedavisi sonrası takip sırasında sadece bir lezyonda (%1.9) tedavi edilen alanda rezidü saptandı. Takiplerde 50 lezyonda (%98.0) total ablasyon sağlandı. Lokal tümör büyümesi ise sekiz hastanın 9 lezyonunda (%17.6) gelişti. Yirmi iki hastada (%62.8) ise takiplerinde farklı bir karaciğer bölgesinde yeni bir lezyon geliştiği görüldü. RFA işlemi sonrası bir hastada kolesistit, iki hastada ise intraperitoneal minimal hemoraji gelişti.Sonuç: RFA tedavisi sağlam karaciğer dokusunun korunması, tedavinin direk tümöre yönelik olması, mortalite ve morbiditenin diğer tedavilere kıyasla az olması sebebiyle karaciğer tümörlerinin tedavisinde günümüzde güvenle uygulanabilen bir yöntemdir.

🔖

Cite This Article

YÜKSEL, Y., AYTEKİN, C. (2017). Results of Radiofrequency Ablation Treatment in Primary and Metastatic Liver Cancer. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 51 - Sayı: 3, 225–233. https://ajindex.com/articles/399602

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Dodd GD 3rd, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000; 20: 9-27. [CrossRef] 2. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119: 647-51. [CrossRef] 3. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210: 127-38. [CrossRef] 4. McWilliams JP, Yamamoto S, Raman SS, Loh CT, Lee EW, Liu DM, et al. Percutaneous ablation of hepatocellular carcinoma: current status J Vasc Interv Radiol 2010; 21: 204-13. [CrossRef] 5. Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices J Vasc İnterv Radiol 2010; 21: 179-86. [CrossRef] 6. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003; 197: 759-64. [CrossRef] 7. Lin SM. Recent advances in radiofrequency ablation in the treatment of hepatocellular carcinoma and metastatic liver cancers. Chang Gung Med J 2009; 32: 22-32. 8. Chen MH, Yang W, Yan K, Gao W, Dai Y, Wang YB, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005; 11: 6395-401. [CrossRef] 9. Gillams AR. The use of radiofrequency in cancer. Br J Cancer 2005; 92: 1825-9. [CrossRef] 10. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010; 10: 78. [CrossRef] 11. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-40. [CrossRef] 12. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma _____= 4 cm. Gastroenterology 2004; 127: 1714-23. [CrossRef] 13. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomized controlled trial comparing percutaneous radio-frequency thermal ablation, percutaneous ethanol injection and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-6. [Cr